Emerging data suggest this peptide, a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , may provide a notable development for weight management . Preliminary clinical trials have demonstrated substantial decreases in body mass , possibly exceeding current body composition medications . Nevertheless , further st